Investors from Saudi Arabia and France are set to take a bigger share of Heathrow as shareholders sell their stakes.
Saudi sovereign wealth fund PIF and French private equity group Ardian have offered to buy 37.6 percent of the west London airport for £3.26 billion.
The couple initially agreed to buy the 25 per cent stake being sold by Spanish group Ferrovial for £2.4bn. But as some of Heathrow’s other shareholders have sold, they are buying more.
Under the deal, Ardian will own 22.6 percent of the airport, while Saudi Arabia’s wealth fund will hold 15 percent. Ferrovial will maintain a 5.25 percent stake. Ardian said the deal “reiterates its strong commitment to investing in the UK”.
The French fund earlier this year reached a deal with investment firm Digital 9 Infrastructure to buy Verne Global, the data center and wireless network investor’s crown jewel, for around £450m.
A larger share: Saudi sovereign fund PIF and French private equity group Ardian offered to buy 37.6 percent of the airport.
Ardian bought a 49 per cent stake in London Luton Airport in 2013 before selling its stake to investment manager AMP Capital in 2018.
Saudi Arabia’s wealth fund bought an 80 per cent stake in football club Newcastle United for £300 million in 2021 and has increased its investment in golf.
Share or comment on this article: Investors from Saudi Arabia and France will take a larger share of Heathrow as shareholders sell their stakes.
Some links in this article may be affiliate links. If you click on them, we may earn a small commission. That helps us fund This Is Money and keep it free to use. We do not write articles to promote products. We do not allow any commercial relationship to affect our editorial independence.
You Might Also Like
- Revealed: The only three areas of Britain where you’d now be better off buying rather than renting…
- Inflation fight is ‘not yet done’ warns Fed amid mounting speculation over the outlook for interest rates
- Tesco veteran Jason Tarry to steer John Lewis turnaround with back to basics message
- Novo Nordisk can’t meet demand as sales of its weight-loss drugs rise